Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
RasCal Therapeutics, Inc.
Frontier Medicines Corporation
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
Filamon LTD
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
PMV Pharmaceuticals, Inc
Mayo Clinic
Indiana University
Washington University School of Medicine
Tomsk National Research Medical Center of the Russian Academy of Sciences
Alterome Therapeutics, Inc.
Verastem, Inc.
Xencor, Inc.
Boehringer Ingelheim
Abramson Cancer Center at Penn Medicine
M.D. Anderson Cancer Center
Convalife (Shanghai) Co., Ltd.
University of California, Irvine
M.D. Anderson Cancer Center
ViroMissile, Inc.
University of California, Davis
Replimune Inc.
Massachusetts General Hospital
Pfizer
Sichuan Enray Pharmaceutical Sciences Company
City of Hope Medical Center
Carevive Systems, Inc.
University Hospital, Clermont-Ferrand
University of Pennsylvania
A2 Biotherapeutics Inc.
University of Florida
Pfizer
Tizona Therapeutics, Inc
Essen Biotech
Taipei Veterans General Hospital, Taiwan
National Institutes of Health Clinical Center (CC)
OHSU Knight Cancer Institute
Ulsan University Hospital
Thomas Jefferson University
Baylor College of Medicine
University of Colorado, Denver
Poitiers University Hospital
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Centre Paul Strauss
Roswell Park Cancer Institute
Revolution Medicines, Inc.